As a partner, PhaRA Consulting will use their regulatory affairs expertise to support Rejuvenate Biomed’s clinical and commercial objectives.

Clinical trials and marketing authorizations must follow a certain regulatory path. The path for aging conditions are not yet defined and sarcopenia has only recently been considered as a condition. So a sound regulatory science and strategy are key to engage in dialogue with regulators, payers, and patients, joining forces for successful drug development.

We are happy to have PhaRA Consulting as a Belgian based partner, sharing their expertise and helping us lead the way to a new regulatory attitude towards age related conditions.